A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies

Recruiting now · Phase 1

Conditions studied: Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma (CTCL), NHL (Non-Hodgkin Lymphoma)

In brief

Evaluate the Safety, Pharmacokinetics and Efficacy of CHT101 in Subjects With Relapsed or Refractory T or B Cell Hematological Malignancies

Key facts

Study ID
NCT06914037
Run by
Tianjin Medical University Cancer Institute and Hospital
People needed
24
Starts
2025-03-31
Expected to finish
2028-03-31
Last updated by the study team
2025-04-06

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.